

What is claimed is:

1. A method for treating or preventing vasomotor symptoms in a subject in need thereof, comprising the step of:  
administering to said subject a therapeutically effective amount of at least one dual NRI/SRI compound or pharmaceutically acceptable salt thereof,  
wherein said amount is less than about 37.5 mg/day.
2. A method according to claim 1,  
wherein said amount is less than about 30 mg/day.
3. A method according to claim 1,  
wherein said amount is less than about 25 mg/day.
4. A method according to claim 1,  
wherein said amount is less than about 20 mg/day.
5. A method according to claim 1,  
wherein said amount is less than about 15 mg/day.
6. A method according to claim 1,  
wherein said amount is less than about 10 mg/day.
7. A method according to claim 1,  
wherein said amount is less than about 5 mg/day.
8. A method according to claim 1,  
wherein said dual NRI/SRI compound is a compound selected from the group consisting of venlafaxine, O-desmethyl-venlafaxine, milnacipran, duloxetine, and combinations and pharmaceutically acceptable salts thereof.
9. A method according to claim 1,

wherein said dual NRI/SRI compound is venlafaxine or a pharmaceutically acceptable salt thereof.

10. A method according to claim 1,  
wherein said dual NRI/SRI compound is O-desmethyl-venlafaxine or a pharmaceutically acceptable salt thereof.
11. A method according to claim 1,  
wherein said dual NRI/SRI compound is milnacipran or a pharmaceutically acceptable salt thereof.
12. A method according to claim 1,  
wherein said dual NRI/SRI compound is duloxetine or a pharmaceutically acceptable salt thereof.
13. A method according to claim 1,  
wherein said vasomotor symptom is hot flush.
14. A method according to claim 1,  
wherein said vasomotor symptom is caused by a thermoregulatory dysfunction.
15. A method according to claim 1,  
wherein said subject is human.
16. A method according to claim 15,  
wherein said human is a female.
17. A method according to claim 16,  
wherein said female is pre-menopausal.
18. A method according to claim 16,  
wherein said female is peri-menopausal.

19. A method according to claim 16,  
wherein said female is post-menopausal.
20. A method according to claim 15,  
wherein said human is a male.
21. A method according to claim 20,  
wherein said male is naturally, chemically or surgically andropausal.